Leerink Partners Downgrades Replimune Group to Market Perform, Lowers Price Target to $2

Benzinga Newsdesk www.benzinga.com Negative 94.5%

Neg 94.5% Neu 0% Pos 0%

Leerink Partners analyst Jonathan Chang downgrades Replimune Group (NASDAQ:REPL) from Outperform to Market Perform and lowers the price target from $11 to $2.